101 related articles for article (PubMed ID: 31786193)
1. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
2. Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review.
Shao F; Zhang H; Yang X; Luo X; Liu J
Neoplasma; 2020 Jul; 67(4):715-723. PubMed ID: 32266817
[TBL] [Abstract][Full Text] [Related]
3. Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.
Meng X; Wang H; Zhao J; Hu L; Zhi J; Wei S; Ruan X; Hou X; Li D; Zhang J; Yang W; Qian B; Wu Y; Zhang Y; Meng Z; Guan L; Zhang H; Zheng X; Gao M
Front Oncol; 2020; 10():217. PubMed ID: 32219060
[No Abstract] [Full Text] [Related]
4. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Cai X; Wei B; Li L; Chen X; Liu W; Cui J; Lin Y; Sun Y; Xu Q; Guo W; Gu Y
Int Immunopharmacol; 2020 Nov; 88():106858. PubMed ID: 32795895
[TBL] [Abstract][Full Text] [Related]
5. Apatinib suppresses the Proliferation and Apoptosis of Gastric Cancer Cells via the PI3K/Akt Signaling Pathway.
Jia X; Wen Z; Sun Q; Zhao X; Yang H; Shi X; Xin T
J BUON; 2019; 24(5):1985-1991. PubMed ID: 31786865
[TBL] [Abstract][Full Text] [Related]
6. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
7. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
[TBL] [Abstract][Full Text] [Related]
8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
9. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling.
Tian ZC; Wang JQ; Ge H
J Orthop Translat; 2020 May; 22():132-141. PubMed ID: 32440509
[TBL] [Abstract][Full Text] [Related]
10. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Yuan M; Huang LL; Chen JH; Wu J; Xu Q
Signal Transduct Target Ther; 2019; 4():61. PubMed ID: 31871778
[TBL] [Abstract][Full Text] [Related]
11. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Zhao H; Yao W; Min X; Gu K; Yu G; Zhang Z; Cui J; Miao L; Zhang L; Yuan X; Fang Y; Fu X; Hu C; Zhu X; Fan Y; Yu Q; Wu G; Jiang O; Du X; Liu J; Gu W; Hou Z; Wang Q; Zheng R; Zhou X; Zhang L
J Thorac Oncol; 2021 Sep; 16(9):1533-1546. PubMed ID: 34033974
[TBL] [Abstract][Full Text] [Related]
12. Apatinib suppresses lung cancer stem-like cells by complex interplay between β-catenin signaling and mitochondrial ROS accumulation.
Zhu J; Li X; Liang C; Zhou X; Ge M; Chen Y; Jin J; Yin J; Xu H; Xie C; Zhong C
Cell Death Discov; 2021 May; 7(1):102. PubMed ID: 33980809
[TBL] [Abstract][Full Text] [Related]
13. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Qin S; Li Q; Gu S; Chen X; Lin L; Wang Z; Xu A; Chen X; Zhou C; Ren Z; Yang L; Xu L; Bai Y; Chen L; Li J; Pan H; Cao B; Fang W; Wu W; Wang G; Cheng Y; Yu Z; Zhu X; Jiang D; Lu Y; Wang H; Xu J; Bai L; Liu Y; Lin H; Wu C; Zhang Y; Yan P; Jin C; Zou J
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):559-568. PubMed ID: 33971141
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
[TBL] [Abstract][Full Text] [Related]
15. Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
Grillo E; Corsini M; Ravelli C; Zammataro L; Bacci M; Morandi A; Monti E; Presta M; Mitola S
Cancer Lett; 2021 Jun; 507():80-88. PubMed ID: 33744390
[TBL] [Abstract][Full Text] [Related]
16. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer.
Zhao J; Lin X; Meng D; Zeng L; Zhuang R; Huang S; Lv W; Hu J
Front Oncol; 2020; 10():578315. PubMed ID: 33324555
[TBL] [Abstract][Full Text] [Related]
18. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
[TBL] [Abstract][Full Text] [Related]
19. VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways.
Zheng B; Zhou C; Qu G; Ren C; Yan P; Guo W; Yue B
Front Oncol; 2020; 10():543562. PubMed ID: 33014879
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6-mediated epigenetic control of the VEGFR2 gene induces disorganized angiogenesis in human breast tumors.
Hegde M; Guruprasad KP; Ramachandra L; Satyamoorthy K; Joshi MB
J Biol Chem; 2020 Aug; 295(34):12086-12098. PubMed ID: 32636303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]